Revacept in Symptomatic Carotid Stenosis

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 158 participants.

Also called NCT01645306

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 158 participants (enrolled count) (from the registry)
Sponsor
AdvanceCor GmbH (from the registry)
Registry
  • NCT NCT01645306
Other papers using this trial's data
  • Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Stenosis: A Multicenter Randomized Phase II Trial Stroke, 2022-09 DOI, PubMed 35695006

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Germany, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01645306. Randomized; quadruple masking; primary purpose treatment. Start 2013-03-08 (actual); primary completion 2018-10-05 (actual). Results posted on 2021-01-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Revacept in Symptomatic Carotid Stenosis
Acronym
RevaceptCS02
Condition
Carotid Stenosis
Condition
Atherosclerosis
Condition
Stroke
Condition
Transient-ischaemic Attack
Condition
Amaurosis Fugax
Intervention (Drug)
Revacept
Intervention (Drug)
Placebo
Lead sponsor
AdvanceCor GmbH (class: industry)

Record details

Record id
cardio:ct-nct01645306
Content hash
0e7cb4158c18235280d6f66cb4c9dfb3541987a5703c4a95cb59eb48d952c79f